SUNRISE, FL--(Marketwire - Oct 15, 2012) - NorthStar Biotech, LLC, a consortium of Bioheart, Inc. ( OTCQB : BHRT ) Directors and Shareholders, led by Managing Director Chuck Hart, has launched a series A private placement financing round and intends to raise a maximum capital of $20 million in exchange for 30% of the company.

"With the intellectual property of Bioheart, NorthStar Biotech is well positioned to become a leader in the field of cardiology. We are also pursuing several opportunities which will make it a leader in regenerative medicine," said Chuck Hart, Managing Director of NorthStar Biotech LLC and a Bioheart Director and longtime shareholder.

Bioheart had previously announced the formation of NorthStar Biotech in August of 2012, a consortium formed by major shareholders and insiders to purchase and protect Bioheart's senior debt that was collateralized with its intellectual property and technology. The primary use of the proceeds raised by the private placement is to fund Bioheart efforts including the Phase II/III MARVEL trial with muscle stem cells, the Phase I REGEN trial with gene modified muscle stem cells and the ANGEL trial with adipose derived stem cells.

Bioheart's cell therapy products address an unmet need in the cardiac market by providing true regenerative medicine where the MyoCell product line may regenerate muscle in areas of scar tissue and the LipiCell product may help reduce inflammation and promote the growth of new blood vessels.

About Bioheart, Inc.

Bioheart is committed to maintaining its leading position within the cardiovascular sector of the cell technology industry delivering cell therapies and biologics that help address congestive heart failure, lower limb ischemia, chronic heart ischemia, acute myocardial infarctions and other issues.Bioheart's goals are to cause damaged tissue to be regenerated, when possible, and to improve a patient's quality of life and reduce health care costs and hospitalizations.

Specific to biotechnology, Bioheart is focused on the discovery, development and, subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage and peripheral vascular disease. Its leading product, MyoCell, is a clinical muscle-derived cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. For more information on Bioheart, visit http://www.bioheartinc.com, or visit us on Facebook: Bioheart and Twitter @BioheartInc.

About NorthStar Biotech, LLC

NorthStar Biotech was founded in 2012 and is focused on the development of regenerative medicine for a variety of degenerative diseases.It maintains an exclusive, international license to the products and intellectual property rights of Bioheart, Inc. ("Bioheart").NorthStar is currently raising sums to complete clinical testing required by Bioheart; to create and oversee an international sales force for Bioheart; and to sell and distribute the Bioheart products and Bioheart IP on an international basis.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "would," "estimate," or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Original post:
NorthStar Launches $20 Million Private Placement Round With Proceeds to Fund Bioheart Trials

Comments are closed.